WENCO-INTERNATIONAL
14.9.2022 05:01:37 CEST | Business Wire | Press release
Wenco International Mining Systems Ltd. ("Wenco") is pleased to expand its sales and support to customers in Northern Europe through its new partnership with Rotator Oy, a leading provider of mining equipment and solutions, based in Finland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913006133/en/
This new agreement extends Wenco’s reach with a capable value-added reseller, paving the way for customers in the region to further leverage Wenco’s open and interoperable approach to mining technology.
Wenco is a leading provider of technology solutions to the global mining industry with a comprehensive suite of digital solutions that boost productivity, decrease operating costs, extend equipment life, enhance safety, and give mining companies actionable insights into their operations. Mines realize these benefits through systems for fleet management, machine guidance, safety, and asset health — all grounded in an open systems philosophy that empowers them to freely integrate systems to support their unique business processes, data requirements, and reporting needs.
“We’re very positive about the establishment of this partnership with Rotator,” says Andrew Pyne, President and CEO of Wenco. “They have a very strong presence in the region and an excellent track record of sales and support for Hitachi Construction Machinery, our parent company. We’re looking forward to working closely with Rotator to deliver value through the application of our technologies to their customers in the region.”
Rotator CEO Janne Wartiovaara concurs with Pyne. “We are excited to add Wenco to our Mining offering and look forward to bring more valuable solutions to our customers,” says Janne Wartiovaara.
In addition to solutions for fleet operations, Rotator and Wenco are introducing innovative fatigue management solutions to the market with Wenco’s SmartCap, the only technology proven to eliminate safety incidents caused by fatigue. SmartCap uses EEG to measure operator fatigue, then notify users of reduced ability to resist sleep — before a fatigue-related incident occurs.
Wenco and Rotator formed this partnership due to their shared focus on delivering customer-centric solutions to the mining industry. Founded in 1954, Rotator is one of the most experienced and well-established machine import and after-sales service companies in Finland. Located in Pirkkala with satellite offices in Vantaa, Kuopio, Seinäjoki, Oulu, Rovaniemi, Sotkamo, and Lieto, Rotator is committed to providing reliable, efficient, and safe solutions to customers through Finland and Sweden.
The company’s rich history of support for customers made it a natural partner for Wenco in Northern Europe.
Rotator is now in discussions with mines across Finland and Sweden on how they can advance their digital transformation with Wenco’s solutions. To learn more, please contact Rotator Sales Manager Sami Laitila at sami.laitila@rotator.fi or +35840-8242-495. For all other inquiries into Wenco and its solutions, please contact Wenco Regional Manager Europe, Middle East, and Kazakhstan, Klaus Hansson at khansson@wencomine.com or +971-522-600-596.
About Wenco International Mining Systems
For over 30 years, Wenco International Mining Systems has worked with mining companies to extract unrealized value. In support of this mission, Wenco has developed an integrated suite of solutions to support the digital transformation of the mining industry. Fleet management, asset health, fatigue management, and other technologies join together in the spirit of open interoperability to raise mine productivity and efficiency, lower routine costs, and establish a safe and smooth mining operation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006133/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
